Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2013 April;61(2) > Minerva Cardioangiologica 2013 April;61(2):221-7





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752




Minerva Cardioangiologica 2013 April;61(2):221-7

language: English

Treating telangiectasias: my method

Ferrara F. 1, Ferrara G. 2

1 Studio Flebologico Ferrara, Naples, Italy;
2 Farmacia Ferrara, Durazzano, Italy


Aim: The authors propose a new classification of telangiectasias: conditions involving demonstrated reflux are classified as type A telangiectasias; clustered, spider telangiectasias not related to reflux and with vein diameters of >0.2 mm are classified as type B, while isolated telangiectatic veins of ≤0.2 mm diameter are classed as type C. This histological and pathophysiological approach is the basis for the Authors’ Multi-Therapy Treatment Protocol (MTT).
Methods: The treatment regimen provides for initial treatment of type A telangiectasias with just conventional reflux sclerotherapy, followed three weeks later by treatment of type B telangiectasias with 0.25-0.5% polidocanol foam, associated with both external compression and tumescent vasoconstriction (START technique). This is then followed after a further three months by dermal stimulation with mesoglycan (LIDS technique) to reinforce the district underlying the type C telangiectasias. The MTT Protocol was used on 63 patients (125 limbs). A 12-month follow-up showed the treatment regimen to provide better aesthetic and functional results than classical sclerotherapy, with few adverse effects and greater patient satisfaction.

top of page

Publication History

Cite this article as

Corresponding author e-mail